Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Feb;27(1):41–55. doi: 10.1089/cbr.2011.1097

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2012, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 6. — Relative cytotoxic anti-neoplastic potency of covalent epirubicin-[anti-HER2/neu] immunochemotherapeutics against chemotherapeutic-resistant mammary adenocarcinoma. (▴) epirubicin-(C₃-amide)-[anti-HER2/neu] synthesized utilizing a UV-photoactivated epirubicin-(C₃-amide) intermediate; (♦) epirubicin-(C₁₃-imino)-[anti-HER2/neu] synthesized using N-ɛ-maleimidocaproic acid hydrazide (EMCH); and (▪) epirubicin-(C₃-amide)-[anti-HER2/neu] with epirubicin-(C₃-amide)-[anti-EGFR] as a 50/50 epirubicin-equivalent combination synthesized utilizing succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC). Mammary adenocarcinoma SKBr-3 monolayer populations were incubated with covalent epirubicin-immunochemotherapeutics for 72 hours and cytotoxic potency measured as a function of MTT cell vitality stain intensity relative to matched negative reference controls.